PL3626270T3 - Leczenie chorób sercowo-naczyniowych - Google Patents

Leczenie chorób sercowo-naczyniowych

Info

Publication number
PL3626270T3
PL3626270T3 PL19202854.6T PL19202854T PL3626270T3 PL 3626270 T3 PL3626270 T3 PL 3626270T3 PL 19202854 T PL19202854 T PL 19202854T PL 3626270 T3 PL3626270 T3 PL 3626270T3
Authority
PL
Poland
Prior art keywords
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
PL19202854.6T
Other languages
English (en)
Inventor
Victor Chengwei Shi
Martin Lefkowitz
Adel Remond RIZKALA
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3626270(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3626270T3 publication Critical patent/PL3626270T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PL19202854.6T 2013-08-26 2014-08-26 Leczenie chorób sercowo-naczyniowych PL3626270T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
PL3626270T3 true PL3626270T3 (pl) 2024-04-08

Family

ID=51494327

Family Applications (3)

Application Number Title Priority Date Filing Date
PL14761702T PL3038654T3 (pl) 2013-08-26 2014-08-26 Nowe zastosowanie
PL23202190.7T PL4321157T3 (pl) 2013-08-26 2014-08-26 Nowe zastosowanie kombinacji blokera receptora angiotensyny (arb) z inhibitorem neutralnej endopeptydazy (nepi)
PL19202854.6T PL3626270T3 (pl) 2013-08-26 2014-08-26 Leczenie chorób sercowo-naczyniowych

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL14761702T PL3038654T3 (pl) 2013-08-26 2014-08-26 Nowe zastosowanie
PL23202190.7T PL4321157T3 (pl) 2013-08-26 2014-08-26 Nowe zastosowanie kombinacji blokera receptora angiotensyny (arb) z inhibitorem neutralnej endopeptydazy (nepi)

Country Status (16)

Country Link
US (2) US20160213646A1 (pl)
EP (4) EP3038654B1 (pl)
JP (1) JP6097888B2 (pl)
CY (1) CY1122531T1 (pl)
DK (3) DK4321157T3 (pl)
ES (3) ES2968541T3 (pl)
FI (2) FI3626270T3 (pl)
HR (3) HRP20200060T1 (pl)
HU (3) HUE047186T2 (pl)
LT (3) LT3626270T (pl)
PL (3) PL3038654T3 (pl)
PT (3) PT3038654T (pl)
RS (3) RS59816B1 (pl)
SI (3) SI4321157T1 (pl)
SM (1) SMT202500001T1 (pl)
WO (1) WO2015028941A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20200060T1 (hr) 2013-08-26 2020-04-03 Novartis Ag Nova uporaba
US10562866B2 (en) * 2015-02-06 2020-02-18 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
US20180140579A1 (en) * 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
WO2017063581A1 (zh) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
AU2017215530B2 (en) 2016-02-03 2019-09-12 Novartis Ag Galenic formulations of organic compounds
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
WO2019008485A1 (en) * 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN113286585B (zh) * 2019-09-20 2022-11-08 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
EE9900278A (et) * 1997-01-10 2000-02-15 Merck & Co., Inc. Angiotensiin II antagonistid kasutamiseks sümptomaatilise südamepuudulikkuse ravis
CA2472399C (en) 2002-01-17 2012-02-21 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
US20070054947A1 (en) * 2003-05-16 2007-03-08 Cohn Jay N Pharmaceutical composition comprising valsartan
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
PL2295035T3 (pl) 2007-11-06 2016-11-30 Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)
AR074203A1 (es) 2008-11-22 2010-12-29 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
WO2012027237A1 (en) 2010-08-24 2012-03-01 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
MX378867B (es) 2012-08-24 2025-03-11 Novartis Ag Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular.
HRP20200060T1 (hr) 2013-08-26 2020-04-03 Novartis Ag Nova uporaba
JP2016530282A (ja) * 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用

Also Published As

Publication number Publication date
RS59816B1 (sr) 2020-02-28
US20160213646A1 (en) 2016-07-28
DK3626270T3 (da) 2024-01-15
EP4321157B1 (en) 2024-10-23
RS65037B1 (sr) 2024-02-29
SMT202500001T1 (it) 2025-03-12
DK4321157T3 (da) 2024-12-16
SI3626270T1 (sl) 2024-03-29
HRP20200060T1 (hr) 2020-04-03
LT4321157T (lt) 2025-01-10
DK3038654T3 (da) 2020-02-03
ES2968541T3 (es) 2024-05-10
FI4321157T3 (fi) 2025-01-20
EP4321157A3 (en) 2024-05-15
US20210077461A1 (en) 2021-03-18
PL3038654T3 (pl) 2020-05-18
CY1122531T1 (el) 2021-01-27
ES2767084T3 (es) 2020-06-16
EP4512397A2 (en) 2025-02-26
EP4512397A3 (en) 2025-05-14
LT3626270T (lt) 2024-01-25
WO2015028941A1 (en) 2015-03-05
EP3038654B1 (en) 2019-10-30
PL4321157T3 (pl) 2025-03-03
RS66371B1 (sr) 2025-02-28
HUE069419T2 (hu) 2025-03-28
HRP20240034T1 (hr) 2024-03-29
LT3038654T (lt) 2020-01-27
PT3626270T (pt) 2024-01-11
HUE064634T2 (hu) 2024-04-28
JP6097888B2 (ja) 2017-03-15
HUE047186T2 (hu) 2020-04-28
EP3626270B1 (en) 2023-10-11
ES3001196T3 (es) 2025-03-04
FI3626270T3 (fi) 2024-01-11
PT4321157T (pt) 2025-01-08
EP3038654A1 (en) 2016-07-06
EP3626270A1 (en) 2020-03-25
SI3038654T1 (sl) 2020-02-28
EP4321157A2 (en) 2024-02-14
PT3038654T (pt) 2020-02-04
SI4321157T1 (sl) 2025-03-31
HRP20241763T1 (hr) 2025-03-14
JP2016528303A (ja) 2016-09-15

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
LT3626270T (lt) Širdies ir kraujagyslių ligų gydymas
IL241101B (en) Medicinal uses of empagliflozin
SG11201507121RA (en) Treatment of cataplexy
IL241102B (en) Medicinal uses of empagliflozin
LT2981271T (lt) Empagliflozino terapinis panaudojimas
GB201403083D0 (en) Treatment of cancer
IL241096B (en) Treatment methods
GB201320014D0 (en) Treatment of cardiovascular disease
GB201321628D0 (en) Treatment of disease
GB201314303D0 (en) Treatment of HPV
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201305020D0 (en) Treatment of cancer
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201219092D0 (en) Treatment of cardiovascular disease
GB201320653D0 (en) Treatment of plants
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment